|
The Biomarker Market
Capital Markets
In managing their portfolios, individual and institutional investors in the life
sciences are also turning their attention to the biomarker sector where product
development life cycles are shorter and less risky, allowing for returns to be
realized at a much earlier stage as compared to many other biotechnologies. The
lower amount of capital needed per product allows biomarker companies to build a
robust product portfolio providing additional exit opportunities through product
licensing and/or acquisitions.
Augurex, with its management and advisory team skill set, along with the
technologies that it will strategically develop, is well poised to contribute
significantly to and capitalize on, the burgeoning biomarker market.
|
